INOHIGH SIGNALREGULATORY10-K

INOVIO received FDA acceptance of its BLA for INO-3107 under accelerated approval review, but the FDA raised concerns about eligibility for this pathway and granted only standard 10-month review instead of requested priority review.

This represents a critical regulatory milestone as INO-3107 moves toward potential commercialization for recurrent respiratory papillomatosis, but the FDA's preliminary conclusion questioning accelerated approval eligibility introduces meaningful approval risk. The standard review timeline extending to October 2026 delays potential revenue realization and creates additional uncertainty around the company's path to market.

Comparing 2026-03-12 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

INOVIO's financial position deteriorated meaningfully over the period, with stockholders' equity declining 65% to $24.1M and total assets falling 34% to $74.3M. Cash reserves decreased 33% to $44.3M while current liabilities increased 24%, creating a tighter liquidity profile. Operating losses improved modestly as R&D expenses fell 28% to $54.2M, but the company remains deeply unprofitable with an $84.9M net loss, highlighting the critical importance of successful INO-3107 approval for future viability.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-100%
$1.2M→450

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
-64.8%
$68.5M→$24.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-41.4%
$488K→$286K

Capex reduced 41.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
-37.5%
$97.8M→$61.1M

Current assets declined 37.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-34.4%
$113.2M→$74.3M

Total assets contracted 34.4% — asset sales, write-downs, or balance sheet optimization underway.

Cash & Equivalents
Balance Sheet
-32.7%
$65.8M→$44.3M

Cash declined 32.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-28.3%
$75.6M→$54.2M

R&D spending cut 28.3% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
+23.6%
$35.3M→$43.7M

Current liabilities rose 23.6% — increased short-term obligations, watch current ratio.

Operating Income
P&L
+22.8%
-$112.4M→-$86.8M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+20.8%
-$107.3M→-$84.9M

Net income grew 20.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-18
ADDED
FORM 10-K SUMMARY 74 SIGNATURES 75 CONSOLIDATED FINANCIAL STATEMENTS F- 1 1 PART I ITEM 1.
These risk factors include, but are not limited to, the following: In December 2025, the FDA accepted INOVIO s BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP.
As part of the submission, INOVIO requested a priority review, which is typically 6 months, but the FDA granted a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target date set for October 30, 2026.
In the file acceptance letter the FDA noted as a potential review issue its preliminary conclusion that the company had not provided adequate information to justify eligibility for the accelerated approval pathway.
In January 2026, INOVIO requested a meeting with the FDA to discuss maintaining eligibility for review under the accelerated approval program.
+7 more — sign up free →
REMOVED
FORM 10-K SUMMARY 72 SIGNATURES 73 CONSOLIDATED FINANCIAL STATEMENTS F- 1 1 PART I ITEM 1.
These risk factors include, but are not limited to, the following: We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.
If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States.
In addition, if the FDA and similar regulatory authorities do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device.
We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →